secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0001193125-22-202617
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis exchanges $75.6M of convertible notes for common stock shares
---------------------------------------------------------------------

- Exchanged ~$65.9M principal for 2,036,886 shares; ~$9.7M for 195,809 shares plus additional based on VWAP.
- Transactions expected to close August 1, 2022, subject to customary closing conditions.
- Shares issued to QIBs and institutional accredited investors under Section 4(a)(2) exemption.
- Debt reduction strengthens balance sheet but dilutes existing shareholders by ~2.2M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312522202617/0001193125-22-202617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312522202617/d338727d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-202617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer